AstraZeneca PLC (AZN): What Does Valuation Ratios Tell Us?

Business man trader investor analyst using mobile phone app analytics for cryptocurrency financial stock market analysis analyze graph trading data index investment growth chart on smartphone screen.

AstraZeneca PLC (NASDAQ:AZN) saw a downside of -0.07% to close Tuesday at $67.93 after subtracting -$0.05 on the day. The 5-day average trading volume is 2,449,220 shares of the company’s common stock. It has gained $68.55 in the past week and touched a new high 3 times within the past 5 days. An average of 4,017,970 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 4,816,840.

AZN’s 1-month performance is 2.66% or $1.76 on its low of $65.88 reached on 11/29/22. The company’s shares have touched a 52-week low of $52.65 and high of $71.70, with the stock’s rally to the 52-week high happening on 04/08/22. YTD, AZN has achieved 16.62% or $9.68 and has reached a new high 20 times. However, the current price is down -5.26% from the 52-week high price.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.


Valuation Metrics

AZN stock has a beta of 0.54. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 4.68 while the price-to-book (PB) in the most recent quarter is 5.99, with the price to cash flow ratio at 61.81.

AstraZeneca PLC’s quick ratio for the period ended June 29 was 0.60, with the current ratio over the same period at 0.80. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.67, while the total debt to equity was 0.83.. In terms of profitability, the gross margin trailing 12 months is 79.20%. The trailing 12-month EBITDA margin is 18.41% while for the period ending June 29, AstraZeneca PLC’s operating margin was 5.20%. The firm’s gross profit as reported stood at $24.98 billion against revenue of $37.42 billion.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income shrunk -2753.57% to $112.0 million, while revenue of $0.0 was 100.0% off the previous quarter. Analysts expected AZN to announce $0.77 per share in earnings in its latest quarter, but it posted $0.86, representing a 11.70% surprise. EBITDA for the quarter stood at more than $2.58 billion. AZN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 59.03 billion, with total debt at $31.39 billion.

Let’s look briefly at AstraZeneca PLC (AZN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 27 December was 49.99% to suggest the stock is trending Neutral, with historical volatility in this time period at 16.15%.

The stock’s 5-day moving average is $67.92, reflecting a +0.68% or $0.46 change from its current price. AZN is currently trading +2.60% above its 20-day SMA, +2.47% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by +23.58% and SMA200 by+12.65%.

Stochastic %K and %D was 22.25% and 22.91% and the average true range (ATR) pointed at 0.96. The RSI (14) points at 57.36%, while the 14-day stochastic is at 21.35% with the period’s ATR at 1.02. The stock’s 9-day MACD Oscillator is pointing at -0.36 and -0.69 on the 14-day charts.

Analyst Ratings

In the most recent analyst report for AstraZeneca PLC (NASDAQ: AZN), Credit Suisse downgraded it to a Neutral rating. They previously had an Outperform rating on the stock. Analysts offering their rating for AZN stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate AZN as a “sell,”, while 6 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 2 rates the stock as overweight while 20 have offered a “buy” rating.

What is AZN’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $60.46 and a high of $105.34, with their median price target at $75.75. Looking at these predictions, the average price target given by analysts is for AstraZeneca PLC (AZN) stock is $75.65.


Please enter your comment!
Please enter your name here